title: Regulatory and ethical issues for phase I in utero gene transfer studies.
abstract: Clinical gene transfer research has involved adult and child subjects, and it is expected that gene transfer in fetal subjects will occur in the future. Some genetic diseases have serious adverse effects on the fetus before birth, and there is hope that prenatal gene therapy could prevent such disease progression. Research in animal models of prenatal gene transfer is actively being pursued. The prospect of human phase I in utero gene transfer studies raises important regulatory and ethical issues. One issue not previously addressed arises in applying U.S. research regulations to such studies. Specifically, current regulations state that research involving greater than minimal risk to the fetus and no prospect of direct benefit to the fetus or pregnant woman is not permitted. Phase I studies will involve interventions such as needle insertions through the uterus, which carry risks to the fetus including spontaneous abortion and preterm birth. It is possible that these risks will be regarded as exceeding minimal. Also, some regard the probability of therapeutic benefit in phase I studies to be so low that these studies do not satisfy the regulatory requirement that they "hold out the prospect of direct benefit" to subjects. On the basis of these considerations, investigators and institutional review boards might reasonably conclude that some phase I in utero studies are not to be permitted. This paper identifies considerations that are relevant to such judgments and explores ethically acceptable ways in which phase I studies can be designed so that they are permitted by the regulations.
authors.affiliation: Department of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA. cstrong@uthsc.edu
authors.forename: Carson
authors.initials: C
authors.lastname: Strong
mesh_terms: D017321:Clinical Trials, Phase I as Topic / Q000941:ethics* / Q000331:legislation & jurisprudence*; D028744:Ethics Committees, Research / Q000941:ethics / Q000331:legislation & jurisprudence; D004992:Ethics, Medical; D005260:Female; D005315:Fetal Diseases / Q000628:therapy; D005333:Fetus / Q000473:pathology; D005817:Genetic Counseling; D015316:Genetic Therapy / Q000941:ethics* / Q000331:legislation & jurisprudence*; D006801:Humans; D011247:Pregnancy; D018570:Risk Assessment